Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans.
Ontology highlight
ABSTRACT: Millions of individuals are diagnosed with type 2 diabetes mellitus (T2D), which increases the risk for a plethora of adverse outcomes including cardiovascular events and kidney disease. Metformin is the most widely prescribed medication for the treatment of T2D; however, its mechanism is not fully understood and individuals vary in their response to this therapy. Here, we use a non-targeted, pharmacometabolomics approach to measure 384 metabolites in 33 non-diabetic, African American subjects dosed with metformin. Three plasma samples were obtained from each subject, one before and two after metformin administration. Validation studies were performed in wildtype mice given metformin. Fifty-four metabolites (including 21 unknowns) were significantly altered upon metformin administration, a
SUBMITTER: Rotroff DM
PROVIDER: S-EPMC4906013 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
ACCESS DATA